CVRX Earnings Prediction
The chart below shows how CVRX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CVRX sees a -6.76% change in stock price 10 days leading up to the earnings, and a +7.31% change 10 days following the report. On the earnings day itself, the stock moves by +1.18%. This data can give you a slight idea of what to expect for the next quarter's release.
CVRX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
13.37M
27.23%
13.26%
Gross Margin
83.19%
-0.86%
-0.86%
Operating Margin
-97.29%
7.32%
-17.79%
Net Margin
-97.95%
14.25%
-17.56%
EPS
-0.57
-32.56%
-12.31%
No Data Available
CVRX Earnings Analysis
CVRx, Inc. Common Stock Corporation (CVRX.O) Earnings Conference Call
Positive
Revenue Increase 27%: Total revenue of $13.4 million, an increase of 27% over the third quarter of 2023.
U.S. Revenue Growth: Revenue generated in the U.S. was $12.3 million in the current quarter, reflecting growth of 28% over the same period last year.
Heart Failure Revenue Comparison: Heart Failure revenue in the U.S. totaled $12.2 million in the current quarter, on a total of 391 revenue units compared to $9.4 million in the third quarter of last year, on 303 revenue units.
Reimbursement Wins Achieved: We secured two significant reimbursement wins during the quarter, including a significantly higher DRG payment for inpatient procedures and the approval of Category 1 CPT codes.
Active Implanting Centers Growth: We had a total of 208 active implanting centers compared to 159 on September 30, 2023 and 189 on June 30, 2024.
Negative
Revenue Increase Overview: Total revenue generated was $13.4 million, representing an increase of $2.9 million or 27% compared to the same period last year.
Heart Failure Revenue Comparison: Heart Failure revenue in the US totaled $12.2 million in the current quarter, on a total of 391 revenue units compared to $9.4 million in the third quarter of last year, on 303 revenue units.
R&D Expense Decrease: Research and development expenses for the current quarter were $2.5 million, reflecting a decrease of 7% compared to the same period last year.
SG&A Expense Increase: SG&A expenses increased $6 million or 38% to $21.6 million for the three months ended September 30, 2024 compared to the three months ended September 30, 2023.
Net Loss Comparison: Net loss was $13.1 million or $0.57 per share for the three months ended September 30, 2024 compared to a net loss of $9 million or $0.43 per share for the three months ended September 30, 2023.
CVRX FAQs
How does CVRX typically perform around its earnings report dates?
Is CVRx, Inc. (CVRX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CVRX Earning Call Sentiment
CVRx, Inc. (CVRX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
CVRX.O
3.83%Positive
The earnings call presents a mixed picture. Financial performance shows strong revenue growth, but increased expenses and a widened net loss raise concerns. Positive elements include optimistic guidance and strategic initiatives. However, the equity offering and increased loan could dilute value. The Q&A reveals confidence in reimbursement efforts but lacks clarity on some financial impacts. The neutral rating reflects these balanced factors, with potential for volatility due to unclear guidance and financial adjustments.